Meraviglia V - Search Results

1

Integrated Proteomics Unveils Nuclear PDE3A2 as a Regulator of Cardiac Myocyte Hypertrophy.

Subramaniam G, Schleicher K, Kovanich D, Zerio A, Folkmanaite M, Chao YC, Surdo NC, Koschinski A, Hu J, Scholten A, Heck AJR, Ercu M, Sholokh A, Park KC, Klussmann E, Meraviglia V, Bellin M, Zanivan S, Hester S, Mohammed S, Zaccolo M. Subramaniam G, et al. Among authors: meraviglia v. Circ Res. 2023 Mar 31;132(7):828-848. doi: 10.1161/CIRCRESAHA.122.321448. Epub 2023 Mar 8. Circ Res. 2023. PMID: 36883446 Free PMC article.

2

Generation of two human induced pluripotent stem cell lines, LUMCi020-A and LUMCi021-A, from two patients with Catecholaminergic Polymorphic Ventricular Tachycardia carrying heterozygous mutations in the RYR2 gene.

Meraviglia V, Arendzen CH, Freund C, Atsma DE, Mummery CL, Bellin M. Meraviglia V, et al. Stem Cell Res. 2020 May;45:101764. doi: 10.1016/j.scr.2020.101764. Epub 2020 Apr 8. Stem Cell Res. 2020. PMID: 32315959 Free article.

3

Generation, functional analysis and applications of isogenic three-dimensional self-aggregating cardiac microtissues from human pluripotent stem cells.

Campostrini G, Meraviglia V, Giacomelli E, van Helden RWJ, Yiangou L, Davis RP, Bellin M, Orlova VV, Mummery CL. Campostrini G, et al. Among authors: meraviglia v. Nat Protoc. 2021 Apr;16(4):2213-2256. doi: 10.1038/s41596-021-00497-2. Epub 2021 Mar 26. Nat Protoc. 2021. PMID: 33772245 Free PMC article.

4

Generation of human induced pluripotent stem cell line EURACi006-A and its isogenic gene-corrected line EURACi006-A-1 from an arrhythmogenic cardiomyopathy patient carrying the c.1643delG PKP2 mutation.

Meraviglia V, Ganesh S, Arendzen CH, Freund C, Sommariva E, Rossini A, Bellin M. Meraviglia V, et al. Stem Cell Res. 2021 Jul;54:102426. doi: 10.1016/j.scr.2021.102426. Epub 2021 Jun 8. Stem Cell Res. 2021. PMID: 34134068 Free article.

5

Inflammation in the Pathogenesis of Arrhythmogenic Cardiomyopathy: Secondary Event or Active Driver?

Meraviglia V, Alcalde M, Campuzano O, Bellin M. Meraviglia V, et al. Front Cardiovasc Med. 2021 Dec 20;8:784715. doi: 10.3389/fcvm.2021.784715. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34988129 Free PMC article. Review.

6

Toward Human Models of Cardiorenal Syndrome in vitro.

Gabbin B, Meraviglia V, Mummery CL, Rabelink TJ, van Meer BJ, van den Berg CW, Bellin M. Gabbin B, et al. Among authors: meraviglia v. Front Cardiovasc Med. 2022 May 26;9:889553. doi: 10.3389/fcvm.2022.889553. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35694669 Free PMC article. Review.

7

Generation of human induced pluripotent stem cell line LUMCi027-A and its isogenic gene-corrected line from a patient affected by arrhythmogenic cardiomyopathy and carrying the c.2013delC PKP2 mutation.

Meraviglia V, Arendzen CH, Tok M, Freund C, Maione AS, Sommariva E, Bellin M. Meraviglia V, et al. Stem Cell Res. 2020 Jul;46:101835. doi: 10.1016/j.scr.2020.101835. Epub 2020 May 5. Stem Cell Res. 2020. PMID: 32485643 Free article.

8

Role of microRNAs in arrhythmogenic cardiomyopathy: translation as biomarkers into clinical practice.

Alcalde M, Toro R, Bonet F, Córdoba-Caballero J, Martínez-Barrios E, Ranea JA, Vallverdú-Prats M, Brugada R, Meraviglia V, Bellin M, Sarquella-Brugada G, Campuzano O. Alcalde M, et al. Among authors: meraviglia v. Transl Res. 2023 Sep;259:72-82. doi: 10.1016/j.trsl.2023.04.003. Epub 2023 Apr 25. Transl Res. 2023. PMID: 37105319 Free article. Review.

9

Desmosomal protein degradation as an underlying cause of arrhythmogenic cardiomyopathy.

Tsui H, van Kampen SJ, Han SJ, Meraviglia V, van Ham WB, Casini S, van der Kraak P, Vink A, Yin X, Mayr M, Bossu A, Marchal GA, Monshouwer-Kloots J, Eding J, Versteeg D, de Ruiter H, Bezstarosti K, Groeneweg J, Klaasen SJ, van Laake LW, Demmers JAA, Kops GJPL, Mummery CL, van Veen TAB, Remme CA, Bellin M, van Rooij E. Tsui H, et al. Among authors: meraviglia v. Sci Transl Med. 2023 Mar 22;15(688):eadd4248. doi: 10.1126/scitranslmed.add4248. Epub 2023 Mar 22. Sci Transl Med. 2023. PMID: 36947592

10

RagD auto-activating mutations impair MiT/TFE activity in kidney tubulopathy and cardiomyopathy syndrome.

Sambri I, Ferniani M, Campostrini G, Testa M, Meraviglia V, de Araujo MEG, Dokládal L, Vilardo C, Monfregola J, Zampelli N, Vecchio Blanco FD, Torella A, Ruosi C, Fecarotta S, Parenti G, Staiano L, Bellin M, Huber LA, De Virgilio C, Trepiccione F, Nigro V, Ballabio A. Sambri I, et al. Among authors: meraviglia v. Nat Commun. 2023 May 15;14(1):2775. doi: 10.1038/s41467-023-38428-2. Nat Commun. 2023. PMID: 37188688 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page